{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:43:02Z","timestamp":1785595382991,"version":"3.56.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.euroneuro.2021.03.006","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T15:12:37Z","timestamp":1618326757000},"page":"69-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Psychonauts\u2019 psychedelics: A systematic, multilingual, web-crawling exercise"],"prefix":"10.1016","volume":"49","author":[{"given":"Valeria","family":"Catalani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Martin","family":"Corkery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Guirguis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Napoletano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Arillotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Zangani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Schifano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2021.03.006_bib0001","unstructured":"Abdulrahim, D., Bowden-Jones, O., 2015. Guidance on the Clinical Management of Acute and Chronic Harms of Club Drugs and Novel Psychoactive Substances [WWW Document]. URL http:\/\/neptune-clinical-guidance.co.uk\/clinical-guidance-2\/"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0002","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.forsciint.2008.11.001","article-title":"A fatal poisoning involving Bromo-Dragonfly","volume":"183","author":"Andreasen","year":"2009","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0003","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fnins.2020.00149","article-title":"Novel opioids: systematic web crawling within the e-psychonauts\u2019 scenario","volume":"14","author":"Arillotta","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0004","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.forsciint.2005.04.022","article-title":"Nonfatal and fatal DOB (2,5-dimethoxy-4-bromamphetamine) overdose","volume":"153","author":"Bal\u00edkov\u00e1","year":"2005","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0005","doi-asserted-by":"crossref","first-page":"73474","DOI":"10.1155\/2014\/734749","article-title":"25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug","volume":"2014","author":"Bersani","year":"2014","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0006","first-page":"9","article-title":"Phencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug","volume":"8","author":"Bey","year":"2007","journal-title":"Calif. J. Emerg. Med."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0007","series-title":"A Magick Life: A Biography of Aleister Crowley","author":"Booth","year":"2000"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0008","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1124\/mol.106.028720","article-title":"Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists","volume":"70","author":"Braden","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0009","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/dta.2222","article-title":"Return of the lysergamides. Part IV: analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)","volume":"10","author":"Brandt","year":"2018","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0010","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/dta.2613","article-title":"Return of the lysergamides. Part V: analytical and behavioural characterization of 1-butanoyl- d -lysergic acid diethylamide (1B-LSD)","volume":"11","author":"Brandt","year":"2019","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0011","doi-asserted-by":"crossref","DOI":"10.1111\/j.1749-6632.2011.06199.x","article-title":"Designer drugs: a medicinal chemistry perspective","author":"Carroll","year":"2012","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0012","series-title":"Liber Null & Psychonaut","author":"Carroll","year":"1987"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0013","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3389\/fpsyt.2020.632405","article-title":"Identifying new\/emerging psychoactive substances at the time of COVID-19; a web-based approach","volume":"11","author":"Catalani","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0014","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fpsyt.2020.00767","article-title":"COVID-19: the hidden impact on mental health and drug addiction","volume":"11","author":"Chiappini","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/hup.2299","article-title":"Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project","volume":"28","author":"Corazza","year":"2013","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0016","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.pnpbp.2012.05.022","article-title":"The recreational tryptamine 5-MeO-DALT (N,N-diallyl-5-methoxytryptamine): a brief review","volume":"39","author":"Corkery","year":"2012","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0017","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2566","article-title":"From concept(ion) to life after death\/the grave: the \u2018natural\u2019 history and life cycle(s) of novel psychoactive substances (NPS)","volume":"32","author":"Corkery","year":"2017","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0018","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s13181-013-0295-x","article-title":"2C or not 2C: phenethylamine designer drug review","volume":"9","author":"Dean","year":"2013","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0019","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.pnpbp.2012.07.011","article-title":"Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project","volume":"39","author":"Deluca","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1874467211666181010154139","article-title":"Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions","volume":"12","author":"Dinis-Oliveira","year":"2018","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0021","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/0011392115596055","article-title":"Information creation on online drug forums: how drug use becomes moral on the margins of science","volume":"66","author":"Duxbury","year":"2018","journal-title":"Curr. Sociol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0022","unstructured":"EDND, 2019. EDND - Login page [WWW Document]. URL https:\/\/ednd2.emcdda.europa.eu\/ednd\/login (accessed 11.18.19)."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0023","unstructured":"EMCDDA-Europol, 2014. EMCDDA\u2013Europol Joint Report on a new psychoactive substance 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe) | www.emcdda.europa.eu. Lisbon."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0024","series-title":"European Drug Report 2019","year":"2019"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0025","unstructured":"EMCDDA, 2019b. The EU Early Warning System on new psychoactive substances (NPS) [WWW Document]. URL https:\/\/www.emcdda.europa.eu\/publications\/topic-overviews\/eu-early-warning-system_en (accessed 10.23.19)."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0026","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bcp.2018.09.024","article-title":"Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: high potency agonists at 5-HT2A receptors","volume":"158","author":"Eshleman","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0027","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/BF02246075","article-title":"Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs II: reassessment of LSD false positives","volume":"121","author":"Fiorella","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0028","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archpsyc.1968.01740030074008","article-title":"On the use and abuse of LSD","volume":"18","author":"Freedman","year":"1968","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0029","unstructured":"Google [WWW Document], 2019. URL https:\/\/www.google.co.uk\/ (accessed 10.24.19)."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/bjp.2008.207","article-title":"Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UK","author":"Green","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0031","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/scientificamerican1210-76","article-title":"Hallucinogens as medicine","volume":"303","author":"Griffiths","year":"2010","journal-title":"Sci. Am."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0032","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.neuropharm.2018.10.037","article-title":"Comparison of the behavioral responses induced by phenylalkylamine hallucinogens and their tetrahydrobenzodifuran (\u201cFLY\u201d) and benzodifuran (\u201cDragonFLY\u201d) analogs","volume":"144","author":"Halberstadt","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2011.01.017","article-title":"Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens","author":"Halberstadt","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0034","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-019-05271-7","article-title":"Emerging threats in addiction: will novel psychoactive substances contribute to exacerbating the ongoing drug overdose epidemic?","author":"Hall","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0035","doi-asserted-by":"crossref","DOI":"10.1186\/1758-2946-5-7","article-title":"InChI \u2013 the worldwide chemical structure identifier standard","author":"Heller","year":"2013","journal-title":"J. Cheminform."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0036","first-page":"240","article-title":"Psychotomimetic drugs; chemical and pharmacological aspects","volume":"8","author":"Hofmann","year":"1959","journal-title":"Acta Physiol. Pharmacol. Neerl."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0037","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00414-018-1882-9","article-title":"Mass poisoning with NPS: 2C-E and Bromo-DragonFly","volume":"133","author":"Iwersen-Bergmann","year":"2019","journal-title":"Int. J. Legal Med."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0038","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/jpet.117.239905","article-title":"Detailed characterization of the in vitro pharmacological and pharmacokinetic properties of N-(2-Hydroxybenzyl)-2, 5-Dimethoxy-4-Cyanophenylethylamine (25CN-NBOH), a highly selective and brain-penetrant 5-HT2A receptor agonist","volume":"361","author":"Jensen","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0039","article-title":"2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOME): a harmful hallucinogen review","author":"Kami\u0144ska","year":"2020","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0040","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/1455072518770351","article-title":"A virtual academy of polydrug use: masters, novices and the art of combinations","volume":"35","author":"Kataja","year":"2018","journal-title":"NAD Nord. Stud. Alcohol Drugs"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0041","doi-asserted-by":"crossref","first-page":"10544","DOI":"10.1523\/JNEUROSCI.3007-12.2013","article-title":"Activation of serotonin 2A receptors underlies the psilocybin-induced effects on \u03b1 oscillations, N170 visual-evoked potentials, and visual hallucinations","volume":"33","author":"Kometer","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0042","series-title":"Methods in Molecular Biology","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-1-4939-7201-2_18","article-title":"Docking and virtual screening in drug discovery","author":"Kontoyianni","year":"2017"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0043","series-title":"The Internationalization of Ayahuasca, Anthropology of Consciousness","author":"Labate","year":"2011"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0044","series-title":"Current Topics in Behavioral Neurosciences","first-page":"45","article-title":"Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways","author":"L\u00f3pez-Gim\u00e9nez","year":"2018"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0045","unstructured":"LSS\/RAB\/DPA\/UNODC, 2016. New psychoactive substances: overview of trends, challenges and legal approaches [WWW Document]. URL https:\/\/www.unodc.org\/documents\/commissions\/CND\/CND_Sessions\/CND_59\/ECN72016_CRP2_V1601405.pdf (accessed 4.16.20)."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0046","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00204-020-02693-7","article-title":"Designer drugs: mechanism of action and adverse effects","volume":"94","author":"Luethi","year":"2020","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0047","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuropharm.2017.07.012","article-title":"Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs)","volume":"134","author":"Luethi","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0048","first-page":"400","article-title":"Novel psychoactive substances and induced phenomena in psychopathology: the lysergic psychoma","volume":"21","author":"Martinotti","year":"2015","journal-title":"Psychopathol. Addict. J. Psychopathol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0049","doi-asserted-by":"crossref","DOI":"10.1097\/FTD.0b013e3181eea318","article-title":"Chemistry, pharmacology, and metabolism of emerging drugs of abuse","author":"Maurer","year":"2010","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0050","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.forsciint.2017.08.028","article-title":"Death after 25C-NBOMe and 25H-NBOMe consumption","volume":"279","author":"Morini","year":"2017","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0051","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/02791072.2011.605661","article-title":"Voice of the psychonauts: coping, life purpose, and spirituality in psychedelic drug users","volume":"43","author":"M\u00f3r\u00f3","year":"2011","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0052","series-title":"Current Topics in Behavioral Neurosciences","first-page":"1","article-title":"Chemistry and structure-activity relationships of psychedelics","author":"Nichols","year":"2018"},{"issue":"2","key":"10.1016\/j.euroneuro.2021.03.006_bib0053","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0054","doi-asserted-by":"crossref","first-page":"6116","DOI":"10.1016\/j.bmc.2008.04.050","article-title":"High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand","volume":"16","author":"Nichols","year":"2008","journal-title":"Bioorganic Med. Chem."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0055","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1021\/cn500292d","article-title":"N-Benzyl-5-methoxytryptamines as potent serotonin 5-HT2 receptor family agonists and comparison with a series of phenethylamine analogues","volume":"6","author":"Nichols","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0056","doi-asserted-by":"crossref","first-page":"977","DOI":"10.15288\/jsad.2013.74.977","article-title":"The NBOMe series: a novel, dangerous group of hallucinogenic drugs","volume":"74","author":"Ninnemann","year":"2013","journal-title":"J. Stud. Alcohol Drugs"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0057","unstructured":"Office for National Statistics, 2019. Deaths related to drug poisoning by selected substances [WWW Document]. URL https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/datasets\/deathsrelatedtodrugpoisoningbyselectedsubstances (accessed 5.5.20)."},{"issue":"9","key":"10.1016\/j.euroneuro.2021.03.006_bib0058","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2174\/1570159X18666200110121333","article-title":"New\/designer benzodiazepines\u201d: an analysis of the literature and psychonauts\u2019 trip reports","volume":"18","author":"Orsolini","year":"2020","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0059","doi-asserted-by":"crossref","first-page":"e2573","DOI":"10.1002\/hup.2573","article-title":"An insight into the deep web; why it matters for addiction psychiatry?","volume":"32","author":"Orsolini","year":"2017","journal-title":"Hum. Psychopharmacol. Clin. Exp."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0060","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1089\/cyber.2014.0486","article-title":"Mind navigators of chemicals\u2019 experimenters? A web-based description of E-psychonauts","volume":"18","author":"Orsolini","year":"2015","journal-title":"Cyberpsychol. Behav. Soc. Netw."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0061","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0924-9338(15)30822-1","article-title":"Navigating in the virtual mind of the web\u2019: the E-psychonauts\u2019 profiling","volume":"30","author":"Orsolini","year":"2015","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0062","article-title":"Evolutionary considerations on the emerging subculture of the E-psychonauts and the novel psychoactive substances: a comeback to the shamanism?","volume":"15","author":"Orsolini","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0063","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1749-6632.1957.tb40738.x","article-title":"A review of the clinical effects of psychotomimetic agents","volume":"66","author":"Osmond","year":"1957","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0064","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00206","article-title":"Acute pharmacological effects of 2C-B in humans: an observational study","volume":"9","author":"Papaseit","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of LSD: a review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0066","article-title":"Dark classics in chemical neuroscience: NBOMes","author":"Poulie","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0067","unstructured":"PubChem [WWW Document], 2019. URL https:\/\/pubchem.ncbi.nlm.nih.gov\/ (accessed 10.24.19)."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0068","unstructured":"PubMed-NCBI [WWW Document], 2019. URL https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/ (accessed 10.24.19)."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0069","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1111\/bph.13128","article-title":"Pharmacological profile of novel psychoactive benzofurans","volume":"172","author":"Rickli","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0070","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","article-title":"Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)","volume":"99","author":"Rickli","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0071","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0072","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1248\/bpb.b14-00315","article-title":"Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats","volume":"38","author":"Sakashita","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0073","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.pnpbp.2005.11.035","article-title":"Drugs on the web; the Psychonaut 2002 EU project","volume":"30","author":"Schifano","year":"2006","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0074","series-title":"Cyberpsychology and Behavior","first-page":"405","article-title":"Importance of cyberspace for the assessment of the drug abuse market: preliminary results from the Psychonaut 2002 project","author":"Schifano","year":"2003"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0075","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.14132","article-title":"The clinical challenges of synthetic cathinones","author":"Schifano","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0076","first-page":"1","article-title":"New\/emerging psychoactive substances and associated psychopathological consequences","author":"Schifano","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0077","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s40429-019-00249-z","article-title":"New psychoactive substances (NPS), psychedelic experiences and dissociation: clinical and clinical pharmacological issues","volume":"6","author":"Schifano","year":"2019","journal-title":"Curr. Addict. Rep."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0078","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20174","article-title":"Novel psychoactive substances of interest for psychiatry","volume":"14","author":"Schifano","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0079","series-title":"Current Topics in Behavioral Neurosciences","first-page":"351","article-title":"NPS: medical consequences associated with their intake","author":"Schifano","year":"2017"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0080","doi-asserted-by":"crossref","DOI":"10.1586\/17512433.2016.1167597","article-title":"Novel psychoactive substances: the pharmacology of stimulants and hallucinogens","author":"Schifano","year":"2016","journal-title":"Exp. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0081","first-page":"77","article-title":"Lysergic acid diethylamide LSD","volume":"42","author":"Seidler","year":"2001","journal-title":"Curr. Ther."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0082","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3109\/15563650.2014.909932","article-title":"Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe","volume":"52","author":"Tang","year":"2014","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0083","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1749-6632.1990.tb16915.x","article-title":"Receptor pharmacology of MDMA and related hallucinogens","volume":"600","author":"Teitler","year":"1990","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0084","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/1570159X13666141210222409","article-title":"Recreational use, analysis and toxicity of tryptamines","volume":"13","author":"Tittarelli","year":"2014","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0085","series-title":"Phenethylamine: Von der Struktur zur Funktion","author":"Trachsel","year":"2013"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0086","unstructured":"UNODC, 2020. COVID-19 is changing the route of illicit drug flows, says UNODC report. Vienna."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0087","unstructured":"UNODC, 2019. UNODC Early Warning Advisory on New Psychoactive Substances [WWW Document]. URL https:\/\/www.unodc.org\/LSS\/Page\/NPS (accessed 4.2.20)."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0088","series-title":"Terminology and Information on Drugs","year":"2016"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0089","series-title":"The Challenge of New Psychoactive Substances","year":"2013"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0090","unstructured":"UNODC EWA, 2020. March 2020- Recently scheduled benzodiazepines Flualprazolam and Etizolam associated with multiple post-mortem and DUID cases in UNODC EWA. URL https:\/\/www.unodc.org\/LSS\/Announcement\/Details\/ad0c279b-b4d4-49f3-b638-cd87755d2d42 (accessed 4.10.20)."},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0091","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-008-1356-8","article-title":"Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines","author":"Winter","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2021.03.006_bib0092","doi-asserted-by":"crossref","DOI":"10.2174\/1570159X18666200302125146","article-title":"The e-psychonauts\u2019 \u2018spiced\u2019 world; assessment of the synthetic cannabinoids\u2019 information available online","volume":"18","author":"Zangani","year":"2020","journal-title":"Curr. Neuropharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X21001619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X21001619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:00:24Z","timestamp":1760378424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X21001619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":92,"alternative-id":["S0924977X21001619"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2021.03.006","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychonauts\u2019 psychedelics: A systematic, multilingual, web-crawling exercise","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2021.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}